JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB167715

Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein

5

(1 Review)

|

(1 Publication)

Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein is a HIV-1 M:B_HXB2R Full Length protein, in the 36 to 507 aa range, expressed in HEK 293 cells, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, ELISA.

View Alternative Names

Envelope glycoprotein gp160, Env polyprotein, env

2 Images
ELISA - Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein (AB167715)
  • ELISA

Supplier Data

ELISA - Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein (AB167715)

Immobilized ab167715 at 5 μg/mL (100 μL/well) can bind Recombinant human CD4 protein (Active) (ab167756) with a linear range of 1-39 ng/mL.

SDS-PAGE - Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein (AB167715)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant HIV-1 gp120 (Du172.17 (mutated E46G, T396A + A497T) protein (AB167715)

SDS-PAGE of reduced ab167715 stained overnight with Coomassie Blue.

Key facts

Purity

>95% SDS-PAGE

Endotoxin level

< 1 EU/µg

Expression system

HEK 293 cells

Tags

His tag C-Terminus

Applications

ELISA, SDS-PAGE

applications

Biologically active

Yes

Biological activity

Measured by its binding ability in a functional ELISA. Immobilized ab167715 at 5 μg/mL (100 μL/well) can bind Recombinant human CD4 protein (Active) (ab167756) with a linear range of 1-39 ng/mL.

Accession

P04578

Animal free

No

Carrier free

Yes

Species

HIV-1 M:B_HXB2R

Reconstitution

Reconstitute at 200 µg/mL in water

Storage buffer

pH: 7.4 Constituents: 100% PBS

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

This product is stable after storage at:

  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.

Sequence info

[{"sequence":"The predicted N-terminus is Thr36.","proteinLength":"Full Length","predictedMolecularWeight":"53.8 kDa","actualMolecularWeight":null,"aminoAcidEnd":507,"aminoAcidStart":36,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":null,"tags":[{"tag":"His","terminus":"C-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
True

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The HIV-1 gp120 protein also known as glycoprotein 120 is an essential component of the HIV envelope protein complex. It is a surface protein expressed on the viral envelope and has a molecular mass of approximately 120 kDa. As part of the Env glycoprotein gp120 plays a critical role in virus entry into host cells by mediating attachment to the CD4 receptor on target cells primarily helper T cells.
Biological function summary

The HIV-1 gp120 protein facilitates viral attachment and entry into host cells. It forms a part of the gp160 precursor which cleaves into two subunits: gp120 and gp41 and together they create the HIV envelope spike complex. Gp120 specifically interacts with the CD4 receptor and subsequently co-receptors such as CCR5 or CXCR4 triggering fusion of the viral and cellular membranes through the gp41 protein.

Pathways

The HIV-1 gp120 protein initiates events critical to the human immunodeficiency virus infection process. It plays a role in the viral attachment and entry pathway which is necessary for HIV to penetrate host immune cells. Gp120's interaction with CD4 and co-receptors like CCR5 is essential for the establishment of infection integrating it into pathways involved in immune evasion and pathogenesis.

HIV-1 gp120 is closely associated with the pathogenesis of acquired immunodeficiency syndrome (AIDS). Its role in mediating viral attachment leads to the depletion of CD4-positive T cells a hallmark of AIDS progression. The interaction between gp120 and host proteins like CD4 and CCR5 not only helps in viral entry but also occasionally triggers immune responses or immune exhaustion intensifying disease severity in some individuals.

Specifications

Form

Lyophilized

General info

Function

Envelope glycoprotein gp160. Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.. Surface protein gp120. Attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Acts as a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells.. Transmembrane protein gp41. Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.

Sequence similarities

Belongs to the HIV-1 env protein family.

Post-translational modifications

Palmitoylation of the transmembrane protein and of Env polyprotein (prior to its proteolytic cleavage) is essential for their association with host cell membrane lipid rafts. Palmitoylation is therefore required for envelope trafficking to classical lipid rafts, but not for viral replication.. Highly glycosylated by host. The high number of glycan on the protein is reffered to as 'glycan shield' because it contributes to hide protein sequence from adaptive immune system.. Specific enzymatic cleavages in vivo yield mature proteins. Envelope glycoproteins are synthesized as an inactive precursor that is heavily N-glycosylated and processed likely by host cell furin in the Golgi to yield the mature SU and TM proteins. The cleavage site between SU and TM requires the minimal sequence [KR]-X-[KR]-R. About 2 of the 9 disulfide bonds of gp41 are reduced by P4HB/PDI, following binding to CD4 receptor.

Subcellular localisation

Host endosome membrane

Product protocols

Target data

Envelope glycoprotein gp160. Oligomerizes in the host endoplasmic reticulum into predominantly trimers. In a second time, gp160 transits in the host Golgi, where glycosylation is completed. The precursor is then proteolytically cleaved in the trans-Golgi and thereby activated by cellular furin or furin-like proteases to produce gp120 and gp41.. Surface protein gp120. Attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. Acts as a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells.. Transmembrane protein gp41. Acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm.
See full target information env mutated E46G + A497T + T396A

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in immunology 8:834 PubMed28824609

2017

Protein-Protein Interaction between Surfactant Protein D and DC-SIGN C-Type Lectin Domain Can Suppress HIV-1 Transfer.

Applications

Unspecified application

Species

Unspecified reactive species

Eswari Dodagatta-Marri,Daniel A Mitchell,Hrishikesh Pandit,Archana Sonawani,Valarmathy Murugaiah,Susan Idicula-Thomas,Béatrice Nal,Maha M Al-Mozaini,Anuvinder Kaur,Taruna Madan,Uday Kishore
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com